Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 5
2014 22
2015 17
2016 17
2017 9
2018 18
2019 4
2020 7
2021 5
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

92 results
Results by year
Filters applied: . Clear all
Page 1
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
Knochelmann HM, Horton JD, Liu S, Armeson K, Kaczmar JM, Wyatt MM, Richardson MS, Lomeli SH, Xiong Y, Graboyes EM, Lentsch EJ, Hornig JD, Skoner J, Stalcup S, Spampinato MV, Garrett-Mayer E, O'Quinn EC, Timmers CD, Romeo MJ, Wrangle JM, Young MRI, Rubinstein MP, Day TA, Lo RS, Paulos CM, Neskey DM. Knochelmann HM, et al. Cell Rep Med. 2021 Oct 19;2(10):100426. doi: 10.1016/j.xcrm.2021.100426. eCollection 2021 Oct 19. Cell Rep Med. 2021. PMID: 34755137 Free PMC article.
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.
Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, Timmers C, Romeo MJ, Krieg C, O'Quinn EC, Horton JD, Dubinett SM, Paulos CM, Neskey DM, Lo RS. Liu S, et al. Cell Rep Med. 2021 Oct 19;2(10):100411. doi: 10.1016/j.xcrm.2021.100411. eCollection 2021 Oct 19. Cell Rep Med. 2021. PMID: 34755131 Free PMC article. Clinical Trial.
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Wang Y, Liu S, Yang Z, Algazi AP, Lomeli SH, Wang Y, Othus M, Hong A, Wang X, Randolph CE, Jones AM, Bosenberg MW, Byrum SD, Tackett AJ, Lopez H, Yates C, Solit DB, Ribas A, Piva M, Moriceau G, Lo RS. Wang Y, et al. Cancer Cell. 2021 Oct 11;39(10):1375-1387.e6. doi: 10.1016/j.ccell.2021.07.023. Epub 2021 Aug 19. Cancer Cell. 2021. PMID: 34416167 Free article.
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.
Hong A, Piva M, Liu S, Hugo W, Lomeli SH, Zoete V, Randolph CE, Yang Z, Wang Y, Lee JJ, Lo SJ, Sun L, Vega-Crespo A, Garcia AJ, Shackelford DB, Dubinett SM, Scumpia PO, Byrum SD, Tackett AJ, Donahue TR, Michielin O, Holmen SL, Ribas A, Moriceau G, Lo RS. Hong A, et al. Cancer Discov. 2021 Mar;11(3):714-735. doi: 10.1158/2159-8290.CD-20-0873. Epub 2020 Dec 14. Cancer Discov. 2021. PMID: 33318037 Free PMC article.
Intracellular C4BPA Levels Regulate NF-κB-Dependent Apoptosis.
Olcina MM, Kim RK, Balanis NG, Li CG, von Eyben R, Graeber TG, Ricklin D, Stucki M, Giaccia AJ. Olcina MM, et al. iScience. 2020 Sep 21;23(10):101594. doi: 10.1016/j.isci.2020.101594. eCollection 2020 Oct 23. iScience. 2020. PMID: 33205012 Free PMC article.
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, Cheung-Lau G, Wohlwender T, Krystofinski P, Vega-Crespo A, Lee CM, Mascaro P, Grasso CS, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Torrejon DY, et al. Cancer Discov. 2020 Aug;10(8):1140-1157. doi: 10.1158/2159-8290.CD-19-1409. Epub 2020 May 28. Cancer Discov. 2020. PMID: 32467343 Free PMC article.
92 results